Project Grant HT94252310359
Award Date 6/1/23
Completion Date 5/31/26
Dollars Obligated $503K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
France
Similar Awards
- The U.S. Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) awarded a $199,908 Project Grant to the Institut National De La Sante Et De La Recherche Medicale (Inserm) to model hemangioblastomas using induced pluripotent stem cells carrying mutations in the von Hippel-Lindau gene. This 2-year project, scheduled for completion by April 30, 2026, aims to transform healthcare for Service Members and the American public through innovative biomedical research. As a...
- This $485,597.91 federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support research at the Universite De Sherbrooke in Canada. The award will fund a 3-year project from August 1, 2024 to July 31, 2027 focused on understanding the "CONTRIBUTION OF ALTERNATIVE SPLICING TO NEUROFIBROMAGENESIS." The research aims to advance scientific knowledge in the area of neurological disorders, which...
- The Defense Health Agency awarded a $697,766 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Murdoch Children's Research Institute in Australia. The grant, awarded on July 15, 2024, will fund a 3-year research project titled "BRAIN CHARTS IN CHILDREN AND ADOLESCENTS WITH NEUROFIBROMATOSIS TYPE 1". The project aims to conduct biomedical research to better understand and characterize brain development in children and adolescents with...
- The Institut Curie, a foreign-owned non-profit organization in France, has been awarded a $1,907,499 Project Grant from the U.S. Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from September 30, 2023 to September 29, 2027, supports the Institut Curie's research on genetic predispositions and tumor markers for uveal melanoma, the most common eye cancer in adults. Specifically, the Institut Curie is conducting...
- This federal Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) provides $1,659,679.00 in funding to the University of California, Los Angeles (UCLA) to conduct research targeting heterogeneity in NF2-mutant tumors. The award period runs from September 15, 2024 through September 14, 2027. The key products and services to be delivered under this grant include innovative scientific research, laboratory studies, and...
- The U.S. Defense Health Agency has awarded a $602,800 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Vlaams Instituut Voor Biotechnologie (VIB), a non-profit research institute in Belgium. The grant, effective September 1, 2024 through August 31, 2027, will fund VIB's research on a "Reduced Combination of Genetic Variants to Predict and Stratify Alzheimer's Disease." This project aims to advance medical solutions for neurodegenerative...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Centre Hospitalier Universitaire Vaudois (CHUV) a $1.184 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. This award supports the development of a clinical-grade spinal cord neuroprosthesis designed to alleviate locomotor deficits in individuals with Parkinson's disease. The research is being conducted at CHUV's facilities in...
- This Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,746,347 to Cedars-Sinai Medical Center to conduct research on "INTERROGATING TUMOR-IMMUNE-NEURON CROSS TALK AT SINGLE-CELL RESOLUTION IN A PANEL OF NOVEL SOMATIC TRANSGENIC NF1 TUMOR MODELS". The primary objective is to develop and validate new mouse models of neurofibromatosis type 1 (NF1) low- and high-grade gliomas, and to determine the role of...
- The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
- The University Health Network (UHN) in Toronto, Canada was awarded a $303,156 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct a study on "LINEAGE TRACING IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND PLEXIFORM NEUROFIBROMAS TO ASSESS TUMORAL HETEROGENEITY AND MECHANISMS OF DRUG RESISTANCE". The award, which runs from June 1, 2024 to May 31, 2026, will support UHN's cutting-edge biomedical research focused...